COVID-19 - G2 Intelligence

A Lasting Impact: COVID-19 and Cancer Screening

Several years after the onset of the COVID-19 pandemic, labs are still dealing with the effects of missed and delayed screenings

Start a Free Trial for immediate access to this article

Already a member? Log in here

Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance

Start a Free Trial for immediate access to this article

Already a member? Log in here

This Lab Institute presentation shares recent enforcement trends and how labs can avoid compliance risks related to these issues.

COVID-19-related schemes dominated recent enforcement efforts, which include a national healthcare fraud enforcement action

Start a Free Trial for immediate access to this article

Already a member? Log in here

Examining what led to record low BB/TM ABPath certification examination pass rates in 2022

Start a Free Trial for immediate access to this article

Already a member? Log in here